Anti-apoptotic effect of umbilical cord cryoextract and its lyophilized form on L929 cells

A. I.  Kaverinska; V. V.  Lazurenko; O. Y.  Zhelezniakov; V. Y.  Prokopiuk

doi:10.15421/0224144

A. I. Kaverinska Institute for Problems of Cryobiology and Cryomedicine NAS of Ukraine
V. V. Lazurenko Kharkiv National Medical University
O. Y. Zhelezniakov Kharkiv National Medical University
V. Y. Prokopiuk Kharkiv National Medical University

Keywords: cell culture; cryoextract; cryopreservation; lyophilization; umbilical cord; apoptosis

Abstract

The umbilical cord cryoextract (UCC) and its lyophilized form (LUCC) contain numerous biologically active components, including growth factors, cytokines, and other regulatory molecules, which may exert an anti-apoptotic effect on cells. This study aimed to determine whether these samples can reduce apoptosis levels in healthy cells, which is particularly relevant in scenarios where apoptosis may be induced by chemotherapeutic agents such as doxorubicin. To evaluate the potential protective effects of umbilical cord cryoextracts, the L929 cell line treated with doxorubicin, a known apoptosis inducer, was selected as a model for assessing the anti-apoptotic properties of UCC and LUCC. In the experiment, L929 cells were cultured in standard Dulbecco's Modified Eagle Medium (DMEM) with the addition of doxorubicin. Experimental results demonstrated that the addition of fetal bovine serum (FBS), UCC, and LUCC significantly reduced apoptosis levels in L929 cells compared to the group treated with doxorubicin alone. In samples with UCC and LUCC, apoptosis levels were comparable to those in the FBS group, indicating a potential supportive and anti-apoptotic effect of both forms of umbilical cord cryoextracts. These findings suggest that both the cryoextract and its lyophilized form may serve as effective agents for reducing apoptosis, maintaining the stability of their active components even post-lyophilization. The results support the potential use of umbilical cord cryoextracts in chemotherapy involving agents such as doxorubicin to mitigate apoptosis in healthy cells and reduce toxic side effects. Further research is needed to elucidate the mechanisms of action of these extracts and to assess their efficacy in vivo, which may open new opportunities for their application in oncology therapy and other medical fields.

References

Alatyyat, S. M., Alasmari, H. M., Aleid, O. A., Abdel-Maksoud, M. S., & Elsherbiny, N. (2020). Umbilical cord stem cells: Background, processing and applications. Tissue and Cell, 65, 101351.

Almuqbil, R. M., Heyder, R. S., Bielski, E. R., Durymanov, M., Reineke, J. J., & da Rocha, S. R. P. (2020). Dendrimer conjugation enhances tumor penetration and efficacy of doxorubicin in extracellular matrix-expressing 3D lung cancer models. Molecular Pharmaceutics, 17(5), 1648–1662.

Bullard, J. D., Lei, J., Lim, J. J., Massee, M., Fallon, A. M., & Koob, T. J. (2019). Evaluation of dehydrated human umbilical cord biological properties for wound care and soft tissue healing. Journal of Biomedical Materials Research, Part B, Applied Biomaterials, 107(4), 1035–1046.

Cao, L., Zhao, S., Yang, Q., Shi, Z., Liu, J., Pan, T., Zhou, D., & Zhang, J. (2021). Chidamide combined with doxorubicin induced p53-driven cell cycle arrest and cell apoptosis reverse multidrug resistance of breast cancer. Frontiers in Oncology, 11, 614458.

Chatterjee, K., Zhang, J., Honbo, N., & Karliner, J. S. (2010). Doxorubicin cardiomyopathy. Cardiology, 115(2), 155–162.

Chen, F., Zhong, X., Dai, Q., Li, K., Zhang, W., Wang, J., Zhao, Y., Shen, J., Xiao, Z., Xing, H., & Li, J. (2022). Human umbilical cord MSC delivered-soluble TRAIL inhibits the proliferation and promotes apoptosis of B-ALL cell in vitro and in vivo. Pharmaceuticals, 15(11), 1391.

Chez, M., Lepage, C., Parise, C., Dang-Chu, A., Hankins, A., & Carroll, M. (2018). Safety and observations from a placebo-controlled, crossover study to assess use of autologous umbilical cord blood stem cells to improve symptoms in children with autism. Stem Cells Translational Medicine, 7(4), 333–341.

Ding, D. C., Shyu, W. C., & Lin, S. Z. (2011). Mesenchymal stem cells. Cell Transplantation, 20(1), 5–14.

Elmore S. (2007). Apoptosis: A review of programmed cell death. Toxicologic Pathology, 35(4), 495–516.

Galieva, L. R., Mukhamedshina, Y. O., Arkhipova, S. S., & Rizvanov, A. A. (2017). Human umbilical cord blood cell transplantation in neuroregenerative strategies. Frontiers in Pharmacology, 8, 628.

Guo, Y., Tang, Y., Lu, G., & Gu, J. (2023). p53 at the crossroads between doxorubicin-induced cardiotoxicity and resistance: A nutritional balancing act. Nutrients, 15(10), 2259.

He, J., Ao, C., Li, M., Deng, T., Zheng, S., Zhang, K., Tu, C., Ouyang, Y., Lang, R., Jiang, Y., Yang, Y., Li, C., & Wu, D. (2024). Clusterin-carrying extracellular vesicles derived from human umbilical cord mesenchymal stem cells restore the ovarian function of premature ovarian failure mice through activating the PI3K/ AKT pathway. Stem Cell Research and Therapy, 15(1), 300.

Heydari, P., Zargar Kharazi, A., & Shariati, L. (2024). Enhanced wound regeneration by PGS/PLA fiber dressing containing platelet-rich plasma: An in vitro study. Scientific Reports, 14(1), 12019.

Hong, B., Lee, S., Shin, N., Ko, Y., Kim, D., Lee, J., & Lee, W. (2018). Bone regeneration with umbilical cord blood mesenchymal stem cells in femoral defects of ovariectomized rats. Osteoporosis and Sarcopenia, 4(3), 95–101.

Ketelut-Carneiro, N., & Fitzgerald, K. A. (2022). Apoptosis, pyroptosis, and necroptosis – oh my! the many ways a cell can die. Journal of Molecular Biology, 434(4), 167378.

Kim, S. Y., Kim, S. J., Kim, B. J., Rah, S. Y., Chung, S. M., Im, M. J., & Kim, U. H. (2006). Doxorubicin-induced reactive oxygen species generation and intracellular Ca2+ increase are reciprocally modulated in rat cardiomyocytes. Experimental and Molecular Medicine, 38(5), 535–545.

Martorana, F., Motta, G., Pavone, G., Motta, L., Stella, S., Vitale, S. R., Manzella, L., & Vigneri, P. (2021). AKT inhibitors: New weapons in the fight against breast cancer? Frontiers in Pharmacology, 12, 662232.

Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004). Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacological Reviews, 56(2), 185–229.

Morana, O., Wood, W., & Gregory, C. D. (2022). The apoptosis paradox in cancer. International Journal of Molecular Sciences, 23(3), 1328.

Peng, Y., Wang, Y., Zhou, C., Mei, W., & Zeng, C. (2022). PI3K/Akt/mTOR pathway and its role in cancer therapeutics: Are we making headway? Frontiers in Oncology, 12, 819128.

Prado, N. O., Lalli, L. A., Blanes, L., Zanette, D. L., & Aoki, M. N. (2023). Lyophilization of molecular biology reactions: A review. Mini Reviews in Medicinal Chemistry, 23(4), 480–496.

Sun, X., Hao, H., Han, Q., Song, X., Liu, J., Dong, L., Han, W., & Mu, Y. (2017). Human umbilical cord-derived mesenchymal stem cells ameliorate insulin resistance by suppressing NLRP3 inflammasome-mediated inflammation in type 2 diabetes rats. Stem Cell Research and Therapy, 8(1), 241.

Sun, Y., Liu, W. Z., Liu, T., Feng, X., Yang, N., & Zhou, H. F. (2015). Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. Journal of Receptor and Signal Transduction Research, 35(6), 600–604.

Tacar, O., & Dass, C. R. (2013). Doxorubicin-induced death in tumour cells and cardiomyocytes: Is autophagy the key to improving future clinical outcomes? The Journal of Pharmacy and Pharmacology, 65(11), 1577–1589.

Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., André, F., & Okkenhaug, K. (2021). PI3K inhibitors are finally coming of age. Nature Reviews. Drug Discovery, 20(10), 741–769.

Wen, X., Jiao, L., & Tan, H. (2022). MAPK/ERK pathway as a central regulator in vertebrate organ regeneration. International Journal of Molecular Sciences, 23(3), 1464.

Wiegand, C., & Hipler, U. C. (2008). Methods for the measurement of cell and tissue compatibility including tissue regeneration processes. GMS Krankenhaushygiene Interdisziplinar, 3(1), Doc12.

Yu, L., Wei, J., & Liu, P. (2022). Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Seminars in Cancer Biology, 85, 69–94.